These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 30254477)

  • 1. Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant
    Petty LA; Henig O; Patel TS; Pogue JM; Kaye KS
    Infect Drug Resist; 2018; 11():1461-1472. PubMed ID: 30254477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam.
    Wenzler E; Scoble PJ
    Infect Dis Ther; 2020 Dec; 9(4):769-784. PubMed ID: 33025557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial.
    Kaye KS; Bhowmick T; Metallidis S; Bleasdale SC; Sagan OS; Stus V; Vazquez J; Zaitsev V; Bidair M; Chorvat E; Dragoescu PO; Fedosiuk E; Horcajada JP; Murta C; Sarychev Y; Stoev V; Morgan E; Fusaro K; Griffith D; Lomovskaya O; Alexander EL; Loutit J; Dudley MN; Giamarellos-Bourboulis EJ
    JAMA; 2018 Feb; 319(8):788-799. PubMed ID: 29486041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections.
    Dhillon S
    Drugs; 2018 Aug; 78(12):1259-1270. PubMed ID: 30128699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Update on Existing and Emerging Data for Meropenem-Vaborbactam.
    Shoulders BR; Casapao AM; Venugopalan V
    Clin Ther; 2020 Apr; 42(4):692-702. PubMed ID: 32147146
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem-vaborbactam: a new weapon in the war against infections due to resistant Gram-negative bacteria.
    Patel TS; Pogue JM; Mills JP; Kaye KS
    Future Microbiol; 2018 Jul; 13(9):971-983. PubMed ID: 29692218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.
    Wunderink RG; Giamarellos-Bourboulis EJ; Rahav G; Mathers AJ; Bassetti M; Vazquez J; Cornely OA; Solomkin J; Bhowmick T; Bishara J; Daikos GL; Felton T; Furst MJL; Kwak EJ; Menichetti F; Oren I; Alexander EL; Griffith D; Lomovskaya O; Loutit J; Zhang S; Dudley MN; Kaye KS
    Infect Dis Ther; 2018 Dec; 7(4):439-455. PubMed ID: 30270406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date.
    Herald F; Burgos RM
    Infect Drug Resist; 2023; 16():555-568. PubMed ID: 36726388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meropenem-vaborbactam: a carbapenem and beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae.
    Lee YR; Baker NT
    Eur J Clin Microbiol Infect Dis; 2018 Aug; 37(8):1411-1419. PubMed ID: 29675787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant
    Shortridge D; Kantro V; Castanheira M
    Microbiol Spectr; 2023 Feb; 11(1):e0450722. PubMed ID: 36622238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Meropenem-Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis.
    Bassetti M; Giacobbe DR; Patel N; Tillotson G; Massey J
    Adv Ther; 2019 Jul; 36(7):1771-1777. PubMed ID: 31098989
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meropenem-vaborbactam for adults with complicated urinary tract and other invasive infections.
    Albin OR; Patel TS; Kaye KS
    Expert Rev Anti Infect Ther; 2018 Dec; 16(12):865-876. PubMed ID: 30372359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
    Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
    Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.
    Wu G; Cheon E
    Expert Opin Pharmacother; 2018 Sep; 19(13):1495-1502. PubMed ID: 30160990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections.
    Bhowmick T; Weinstein MP
    Infect Dis Ther; 2020 Dec; 9(4):757-767. PubMed ID: 33017041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meropenem/Vaborbactam, the First Carbapenem/β-Lactamase Inhibitor Combination.
    Cho JC; Zmarlicka MT; Shaeer KM; Pardo J
    Ann Pharmacother; 2018 Aug; 52(8):769-779. PubMed ID: 29514462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of Ceftazidime-Avibactam, Meropenem-Vaborbactam, and Imipenem/Cilastatin-Relebactam to Target
    Hayden DA; White BP; Bennett KK
    J Pharm Technol; 2020 Oct; 36(5):202-210. PubMed ID: 34752560
    [No Abstract]   [Full Text] [Related]  

  • 20. Meropenem-Vaborbactam in the Treatment of Acute Bacterial Infections.
    Lai CC; Chen CC; Tang HJ
    J Clin Med; 2019 Oct; 8(10):. PubMed ID: 31614430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.